CancerFind™ oncology blood test
An innovative genetic blood test designed for early cancer detection. The test is based on whole-genome DNA methylation analysis, enabling identification of cancer-related processes and their likely location at an early stage. A single sample can be used to screen for up to eight cancer types – from colorectal cancer to ovarian or prostate cancer.
Cancer often develops silently – CancerFind™ helps detect it earlier
Most cancers cause no symptoms in the early stages, which is why up to 60% of cases are detected too late, when treatment options are limited. Traditional approaches – radiological examinations or tumour markers – are not always accurate enough or suitable for frequent use.
The CancerFind™ blood test, based on advanced DNA methylation analysis and artificial intelligence, makes it possible to identify cancer-related changes before they become clinically apparent. It’s a new way to spot risk early – with one simple test.
How does CancerFind™ work and what does it detect?
CancerFind™ analyses DNA fragments circulating in the bloodstream, looking for signs of cancer-related changes even when no symptoms are present. It uses whole-genome methylation sequencing to evaluate genetic patterns characteristic of cancer cells. AI algorithms process the data and provide not only an indication of a potential oncological process, but also a prediction of where in the body it may have started. CancerFind™ assesses:
Presence of a cancer signal (yes / no / suspicious)
Likely cancer location (two most probable sites)
DNA methylation patterns characteristic of cancer cells
Fragmentation and copy-number variation (CNV) changes
Detect cancer while it can still be stopped
CancerFind™ can detect signs of cancer before symptoms appear, enabling timely action – when treatment is most effective. This reliable, safe, evidence-based test helps reduce uncertainty and provides a clearer pathway for next decisions.
Early detection of cancer signals
Helps identify asymptomatic oncological conditions when other methods may not yet show clear changes.
Greater accuracy than standard tumour marker tests
CancerFind™ sensitivity reaches 85.6% and specificity 95.7%, reducing the likelihood of false-positive or false-negative results.
One test – analysis of eight cancer types
Screens for common cancers, including colorectal, lung, breast, pancreatic, and others.
Minimally invasive and safe
Unlike some radiological tests, CancerFind™ involves no radiation – only a single blood sample is needed.
When and for whom is the test recommended?
For people who want preventive cancer screening
Suitable for those who proactively care for their health and want to detect possible oncological changes early, before symptoms appear.
For people over 50 years of age
he risk of many cancers increases with age. The test is especially valuable in this age group, even without any symptoms.
For those with an inherited predisposition to cancer
If close relatives have been diagnosed with cancer, periodic testing may help detect early signs of disease.
For individuals who prefer to avoid invasive or radiation-based tests
CancerFind™ is performed from blood – a safe and painless alternative to many standard screening methods.
CancerFind™ reliability: accuracy and quality metrics
CancerFind™ uses whole-genome methylation sequencing and advanced AI algorithms to provide an accurate assessment of potential cancer processes from a single blood sample. Its sensitivity and specificity help avoid unnecessary anxiety and incorrect conclusions.
95.7% specificity
85.6% overall sensitivity
81.1% accuracy in predicting likely cancer localisation
Early cancer detection with one blood test
Take the CancerFind™ test and find out whether oncological changes may be developing in your body.
For Specialists
All key information in one place – from test performance to clinical value. This section is intended for specialists who want a detailed understanding of the test rationale, structure, and practical applications.
CancerFind™ is intended for early cancer detection in the general population and in higher-risk groups. It helps identify a potential oncological process before symptoms appear, providing both a signal and a predicted location.
The test uses whole-genome methylation sequencing, including analysis of DNA methylation, fragmentation, and copy-number variation (CNV). Data are evaluated using advanced AI algorithms.
From a single sample, CancerFind™ screens eight of the most common solid tumours:
- Colorectal
- Gastric
- Liver
- Pancreatic
- Lung
- Breast
- Prostate
- Ovarian
Results are provided within 17 business days. The report indicates:
- Whether a cancer signal is detected (yes / suspicious / not detected)
- The two most likely locations, if a signal is detected
Specificity: 95.7%
Overall sensitivity: 85.6%
Sensitivity by cancer type:
Colorectal – 100%
Gastric – 65.8%
Liver – 90.9%
Pancreatic – 83.9%
Lung – 84.9%
Breast – 94.7%
Ovarian – 79.7%
Prostate – 83.3%
